AngioDynamics Inc. designs, manufactures and sells a wide range of medical, surgical and diagnostic devices. The devices are generally used in minimally invasive, image-guided procedures. AngioDynamics product offerings fall within three Global Business Units, namely Oncology/Surgery, Endovascular Therapies and Vascular Access. Endovascular Therapies product offerings support the medical areas of Thrombus Management, Atherectomy, Peripheral Products and Venous Insufficiency. The Thrombus Management portfolio includes the proprietary AngioVac venous drainage cannula and circuit as well as catheter directed thrombolytic devices. Vascular Access arm offers advanced imaging equipment to guide the placement of catheters that primarily deliver short-term drug therapies. IGVA procedures include the placement of Peripherally Inserted Central Catheters lines, implantable ports and central venous catheters. Oncology/Surgery division includes Microwave Ablation, Radiofrequency Ablation and NanoKnife product lines....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 4 July 2026
2019-01-03 10:38:00 Thursday ET

American parents often worry about money and upward mobility for their children. A recent New York Times survey suggests that nowadays American parents spen
2023-02-28 11:30:00 Tuesday ET

The Biden Inflation Reduction Act is central to modern world capitalism. As of 2022-2023, global inflation has gradually declined from the peak of 9.8% d
2025-10-11 14:33:00 Saturday ET

Stock Synopsis: With a new Python program, we use, adapt, apply, and leverage each of the mainstream Gemini Gen AI models to conduct this comprehensive fund
2018-05-13 08:33:00 Sunday ET

Incoming New York Fed President John Williams suggests that it is about time to end forward guidance in order to stop holding the financial market's han
2018-10-15 09:33:00 Monday ET

Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties such as cardiovascular medications an
2025-06-05 00:00:00 Thursday ET

Former New York Times team journalist and Pulitzer Prize winner Charles Duhigg describes, discusses, and delves into how we can change our respective lives